BACKGROUND: Oral poliovirus vaccine (OPV) has not been used in the United States since 2000. Type 1 vaccine-derived poliovirus (VDPV) was identified in September 2005, from an unvaccinated Amish infant hospitalized in Minnesota with severe combined immunodeficiency. An investigation was conducted to determine the source of the virus and its means of transmission. METHODS: The infant was tested serially for poliovirus excretion. Investigations were conducted to detect poliovirus infections or paralytic poliomyelitis in Amish communities in Minnesota, neighboring states, and Ontario, Canada. Genomic sequences of poliovirus isolates were determined for phylogenetic analysis. RESULTS: No source for the VDPV could be identified. In the index community, 8 (35%) of 23 children tested, including the infant, had evidence of type 1 poliovirus or VDPV infection. Phylogenetic analysis suggested that the VDPV circulated in the community for approximately 2 months before the infant's infection was detected and that the initiating OPV dose had been given before her birth. No paralytic disease was found in the community, and no poliovirus infections were found in other Amish communities investigated. CONCLUSIONS: This is the first demonstrated transmission of VDPV in an undervaccinated community in a developed country. Continued vigilance is needed in all countries to identify poliovirus infections in communities at high risk of poliovirus transmission.
BACKGROUND: Oral poliovirus vaccine (OPV) has not been used in the United States since 2000. Type 1 vaccine-derived poliovirus (VDPV) was identified in September 2005, from an unvaccinated Amish infant hospitalized in Minnesota with severe combined immunodeficiency. An investigation was conducted to determine the source of the virus and its means of transmission. METHODS: The infant was tested serially for poliovirus excretion. Investigations were conducted to detect poliovirus infections or paralytic poliomyelitis in Amish communities in Minnesota, neighboring states, and Ontario, Canada. Genomic sequences of poliovirus isolates were determined for phylogenetic analysis. RESULTS: No source for the VDPV could be identified. In the index community, 8 (35%) of 23 children tested, including the infant, had evidence of type 1 poliovirus or VDPV infection. Phylogenetic analysis suggested that the VDPV circulated in the community for approximately 2 months before the infant's infection was detected and that the initiating OPV dose had been given before her birth. No paralytic disease was found in the community, and no poliovirus infections were found in other Amish communities investigated. CONCLUSIONS: This is the first demonstrated transmission of VDPV in an undervaccinated community in a developed country. Continued vigilance is needed in all countries to identify poliovirus infections in communities at high risk of poliovirus transmission.
Authors: Kimberly M Thompson; Gregory S Wallace; Radboud J Duintjer Tebbens; Philip J Smith; Albert E Barskey; Mark A Pallansch; Kathleen M Gallagher; James P Alexander; Gregory L Armstrong; Stephen L Cochi; Steven G F Wassilak Journal: Public Health Rep Date: 2012 Jan-Feb Impact factor: 2.792
Authors: W J Lodder; A M Buisman; S A Rutjes; J C Heijne; P F Teunis; A M de Roda Husman Journal: Appl Environ Microbiol Date: 2012-03-23 Impact factor: 4.792
Authors: Radboud J Duintjer Tebbens; Mark A Pallansch; Jong-Hoon Kim; Cara C Burns; Olen M Kew; M Steven Oberste; Ousmane M Diop; Steven G F Wassilak; Stephen L Cochi; Kimberly M Thompson Journal: Risk Anal Date: 2013-03-07 Impact factor: 4.000
Authors: A Battistone; G Buttinelli; S Fiore; C Amato; P Bonomo; A M Patti; A Vulcano; M Barbi; S Binda; L Pellegrinelli; M L Tanzi; P Affanni; P Castiglia; C Germinario; P Mercurio; A Cicala; M Triassi; F Pennino; L Fiore Journal: Appl Environ Microbiol Date: 2014-08 Impact factor: 4.792
Authors: Kasper H Kisjes; Radboud J Duintjer Tebbens; Gregory S Wallace; Mark A Pallansch; Stephen L Cochi; Steven G F Wassilak; Kimberly M Thompson Journal: J Infect Dis Date: 2014-11-01 Impact factor: 5.226
Authors: William T Shearer; Thomas A Fleisher; Rebecca H Buckley; Zuhair Ballas; Mark Ballow; R Michael Blaese; Francisco A Bonilla; Mary Ellen Conley; Charlotte Cunningham-Rundles; Alexandra H Filipovich; Ramsay Fuleihan; Erwin W Gelfand; Vivian Hernandez-Trujillo; Steven M Holland; Richard Hong; Howard M Lederman; Harry L Malech; Stephen Miles; Luigi D Notarangelo; Hans D Ochs; Jordan S Orange; Jennifer M Puck; John M Routes; E Richard Stiehm; Kathleen Sullivan; Troy Torgerson; Jerry Winkelstein Journal: J Allergy Clin Immunol Date: 2014-02-28 Impact factor: 10.793
Authors: Kimberley S M Benschop; Harrie G van der Avoort; Edin Jusic; Harry Vennema; Rob van Binnendijk; Erwin Duizer Journal: Appl Environ Microbiol Date: 2017-06-16 Impact factor: 4.792